Update

Novo Nordisk pushes into Russia with new insulin manufacturing facility

By Zachary Brennan contact

- Last updated on GMT

Novo Nordisk pushes into Russia with new insulin manufacturing facility

Related tags: Novo nordisk, Carbon dioxide

Novo Nordisk has opened a new manufacturing facility in Russia for the formulation and filling of insulin as a diabetes treatment. 

This is the first and only greenfield facility for the manufacturing of modern insulin in Russia, according to Novo, which also says it has set up environmental targets for carbon dioxide emission, water consumption and use of energy.

"The factory was built to ensure that patients in Russia will continue to have access to modern insulin from Novo Nordisk... The factory furthermore supports the Russian authorities' Pharma 2020 strategy on local production of pharmaceuticals​," Henrik Bendix Dahl, General Manager, Novo Nordisk Russia, told In-Pharmatechnologist.com.

The new GMP production facility, located in Technopark Grabtsevo in the Kaluga region of Russia, will add about 150 new jobs to the Russian economy and help to provide both Penfill ​cartridges and FlexPen prefilled insulin injection pens for the Russian market.

"The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day​," said Lars Rebien Sørensen, CEO of Novo Nordisk. 

Novo Nordisk also has production sites in Denmark, Brazil – which was injected with $200m back in 2007​ -- China, France and the US.

The company has been busy in recent months with its manufacturing operations. In October, the company was hit with a subpoena​ over a Danish insulin and hemophilia treatment manufacturing site over alleged issues. Also in October, the company bought a manufacturing facility in New Hampshire​, where it’s looking to add 90 new employees.

The Danish drugmaker is also working to develop a new way to deliver insulin orally​.

Related topics: Processing, Delivery formulations

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more